Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Quralis Corp.
Headquarters: Cambridge, MA, United States of America
Website: https://quralis.com/
Year Founded: 2016
Status: Private
BioCentury | Feb 27, 2025
Guest Commentary
The next rare disease roadblock: American innovation moving ex-U.S.
As regulatory hurdles push early-stage trials out of the U.S., three things FDA can do to bring them back
BioCentury | Nov 15, 2024
Finance
Syncona building Slingshot incubator; Trace launches with $101M
BioCentury’s Financial Report also features venture rounds for Alentis and Metsera; follow-ons for Zai Lab and 89bio
BioCentury | Sep 4, 2024
Discovery & Translation
The inextricable linkage of biomarkers and target discovery
Back to School 2024: How biomarkers can help validate targets while bringing precision medicine to I&I and neurology
BioCentury | Sep 3, 2024
Discovery & Translation
Neurology’s human data revolution
Back to School 2024 looks at how neuroscience companies are reducing to practice the concept of human-first discovery
BioCentury | Sep 3, 2024
Discovery & Translation
Eyes on the target: Drug discovery’s new paradigm
Back to School 2024: Can biotech write a more successful playbook for translating from target to product?
BioCentury | Jun 12, 2024
Management Tracks
Former Fusion CFO Crowley joins Centessa
Weinhoff becomes CBO. Plus: QurAlis pads C-suite and updates from PepGen, C4 and more
BioCentury | Jun 11, 2024
Product Development
What neuroscience biotechs need to consider when pitching VCs, pharmas
Investors and partners may have different priorities, but all want to see programs grounded in human data
BioCentury | Jun 4, 2024
Deals
Deals Report: Two pharmas license neuro assets, and M&A momentum continues
Plus: Galapagos-Adaptimmune enter TCR T cell deal, and digital therapeutics pioneer Akili opts for merger
BioCentury | May 21, 2024
Discovery & Translation
Big data for a rare disease: FNIH takes on ALS
In partnership with FDA, industry and disease foundations, FNIH is creating a one-stop shop for data on the rare disease to spur diagnostics and therapeutics development
BioCentury | Mar 30, 2023
Finance
March 29 Quick Takes: Final close for LSP Dementia Fund
Plus: Bluebird will likely miss submission goal for lovo-cel and updates from Merck, Blueprint, Intarcia, J&J
Items per page:
1 - 10 of 25